Heparin Versus Taurolidine to Bloodstream Infection Prevention Related in Central Venous Catheter in Children

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-09-30

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Clinical trial, that aim is evaluation of the use of taurolidine and heparin in the prevention of bloodstream infection in venous catheter in children with intestinal failure.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Continuous or Intermittent for Keeping Arterial Catheter in Children: A Randomized Clinical Trial

NCT01097031

Blood Pressure

COMPLETED

Hemostatic Profiles in Pediatric CKD

NCT05064267

Kidney Disease, Chronic Pediatric Kidney Disease Renal Insufficiency, Chronic +1 more

COMPLETED

Image Guidance for Improved Vessel Cannulation in Pediatric Patients

NCT04031495

Central Vein Cannulation

COMPLETED NA

Ultrasound-guided Peripheral Vascular Access in Children

NCT02556541

Ultrasonography Vascular Access Devices Pediatrics

UNKNOWN NA

Thrombosis Outcomes in Pediatric Venous Thromboembolism

NCT03068923

Venous Thromboembolism

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Will be collected data about sociodemographics : date of birth, hospitalization and which is use (taurolidine or heparin), sex, underlying disease and associated co-morbidities.

About central venous catheter will be collect: catheter type in each period, the number of lumens, date of insertion of each catheter usage time, reason for removal of the catheter insertion site and catheter material (silicone or polyurethane ).

Data relating to parenteral nutrition will also be collected: osmolarity of parenteral nutrition, infusion time every 24 hours and concentration of glucose parenteral nutrition bag.

It will be used for aseptic handling technique of the solutions, as well as for handling the connections of the central catheter. For preparation and administration of taurolidine and heparin is used an operations manual that was made for the authors. Patients are divided into two groups: taurolidine or heparin.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Catheter-Related Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Taurolidine

Taurolidine be held in each infusion central venous catheter lumen with a volume that varies in accordance with the lumen via the catheter. The solution will be administered every day while the patient is on break from parenteral nutrition, and the catheter solution residence time will be the same time of the break from parenteral nutrition. Taurolidine infusion will be used TaurolockTM with ampoule presentation containing 3 ml.

Group Type ACTIVE_COMPARATOR

Taurolidine

Intervention Type DRUG

taurolidine in central catheter lumen

Heparin

Heparin be held in each infusion central venous catheter lumen with a volume that varies in accordance with the lumen via the catheter. The solution will be administered every day while the patient is on break from parenteral nutrition, and the catheter solution residence time will be the same time of the break from parenteral nutrition. Heparin infusion will be used with heparin solution contain 50 International Unit (UI)/ml.

Group Type ACTIVE_COMPARATOR

Heparin

Intervention Type DRUG

heparin in central venous catheter lumen

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Taurolidine

taurolidine in central catheter lumen

Intervention Type DRUG

Heparin

heparin in central venous catheter lumen

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Taurolock heparin solution

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The population will consist of patients 30 days of life to fourteen years old, admitted to the pediatric inpatient units, with intestinal failure receiving parenteral nutrition through a central venous catheter and at least eight weeks of use forecast.

Exclusion Criteria

* Children will be excluded other associated diseases that occur with frequent use of antibiotics, for example, cystic fibrosis, primary or acquired immunodeficiency. Also excluded are the children admitted that they are not accompanied by a responsible family recognition, or accompanied by responsible under the age of 18 years. Children with allergic reactions to the use of some of the solutions (taurolidine or heparin) will be suspended medication and receive appropriate treatment. Although these children have stopped the use of medication, will be followed according to the assessment protocol by the end of the study.

Minimum Eligible Age

30 Days

Maximum Eligible Age

14 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No